The Association of G9a Protein and Outcome of Patients With Endometrial Cancer

Not Applicable

Completed

• Conditions: Outcome of Endometrial Cancer
• Interventions: Other: no drug

• Registration Number: NCT01271764
• Lead Sponsor: Far Eastern Memorial Hospital

Brief Summary

Tumor invasion and metastasis are the major causes of cancer-related death. Some studies have found that histone methyltransferases, such as EZH2, specifically affect metastasis in breast, gastric and prostate cancer. The functional roles of other members of the HMT family such as G9a in cancer remain obscure. Therefore, the investigators will investigate whether G9a have a role in recurrence/metastasis of endometrial cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01
• Study First Submitted: 2011-01-05
• Study First Submitted QC: 2011-01-06
• Study First Posted: 2011-01-07
• Primary Completion: 2012-07
• Status Verified: 2012-09
• Study Completion: 2012-09
• Last Update Submitted: 2012-09-25
• Last Update Posted: 2012-09-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 97

Inclusion Criteria

• all cases with endometrial cancer underwent staging operation

Exclusion Criteria

• nil

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
endometrial cancer	no drug	-

Primary Outcome Measures

Name	Time	Method
The role of G9a protein in endometrial cancer	overall survial, disease-free survival	We will correlate the G9a protein and outcome of endometrial cancer

Trial Locations

Locations (1)

Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital; 🇨🇳 Banqiao, New Taipei, Taiwan